窑Technology and Method 窑 Bronchial mucosa is naturally autofluorescent. When irradiated by blue laser light (442 nm in wavelength), fluorescent substances underneath the bronchial mucosa are stimulated and subsequently emit green fluorescence (520 nm in wavelength) and red fluorescence (630 nm in wavelength). Because the ratio of green to red fluorescence varies according to the phenotype of the examined tissues, observed images may display various colors. Thus, when the tissues change from normal mucosa to hypertrophy, carcinoma in situ, or even invasive carcinoma, the observed colors also change, yielding decreased green fluorescence and increased red fluorescence. Although tiny lesions are usually undetectable using standard light, they may be detected by a highresolution imaging system that can distinguish subtle differences in autofluorescence. The autofluorescence bronchoscope (AFB) is a white light bronchoscope (WLB) updated with the addition of a blue laser. This new technology can detect tiny lesions in the bronchial mucosa by exploiting the autofluorescent nature of the tissue [1, 2] . Autofluorescence bronchoscopy has already been reported in some developed countries [3] , but never in China. Hence, this paper compares the values of the AFB and WLB based on the analysis of 136 cases examined in our hospital from September 2009 to May 2010.
From September of 2009 to May of 2010, 136 patients, including 95 males and 41 females with a median age of 61.5 years (ranged from 25 to 84 years), received both AFB and WLB examinations. Of the 136 patients, 125 received examinations for diagnosis and 11 received examinations for postoperative recheck. The number of central pulmonary lesions, peripheral pulmonary lesions, and mediastinal lesions were 46, 84, and 6, respectively.
The autofluorescence bronchoscope BFF260 (OLYMPUS, Japan) has functions shared by both the AFB and WLB and can shift from one to the other freely. The xenon lamp CV260L was also from OLYMPUS (Japan).
For painless bronchoscope examinations, patients received local anesthesia on the glottis and airway, as well as continuous venous anesthesia. For local anesthesia, 1% amethocaine was inhaled through ultrasonic nebulization for 1530 min. Subsequently, sprays of 7% lidocaine were administered to the larynx 3 times at 5minute intervals, with 23 pushes per time. Simultaneously, 1% lidocaine was also sprayed in the local mucosa. For venous anesthesia, patients received 23 mg midazolam, 36 mg propofolum, and 1 mg morphine. Autonomous respiration was reserved and mask ventilation was used.
The bronchoscope was pushed into the airway through the mouth. First, in the WLB state, the glottis, trachea, carina, and bronchi (segments 0V) were examined, and cartilage rings, mucosa, blood vessels, secretions, and neoplasms were observed. Suspicious lesions, such as hyperemia, edema, thickness, nodules, color changes and regression, or bucking of vessels, were recorded. Next, the bronchoscope was shifted to the AFB state, and all bronchi (segments 0V), especially suspicious areas discovered by the WLB, were observed. All abnormalities detected by the AFB were also recorded. When observation was over, biopsies were collected from suspicious lesions for further pathological examination. Biopsies of normal mucosa were also randomly performed as controls.
For patients who underwent surgery, endobronchial ultrasoundguided transbronchial needle aspiration (EBUSTBNA) or thoracotomy was performed to determine a pathological diagnosis. For peripheral lesions or extrabronchial lesions that could not be diagnosed by bronchoscope, EBUSTBNA or thoracotomy was also performed for further pathological diagnosis. For patients with abnormal mucosal lesions, biopsies of affected areas were collected through thoracotomy for verification.
Classification standards in reference [4] were adopted in our study. Under the WLB state, lesions were classified into The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were used to evaluate the diagnostic power of the AFB and WLB. The aforementioned statistics were compared by McNemar test using SPSS13.0. The significance level was set to 琢 = 0.05.
All examinations in our study were completed successfully without examination death or severe complications. In total, 138 examinations were completed with the intent of primary diagnosis or postoperative recheck. For primary diagnosis, 126 examinations were performed on 125 patients (one patient was examined before and after neoadjuvant chemotherapy). For postoperative recheck, 12 examinations were performed on 11 patients diagnosed with adenocarcinoma (7 cases), squamous cell carcinoma (3 cases), or adenoid cystic carcinoma (1 case) and surgically treated with lobectomy (7 cases), trachea ring resection (2 cases), bronchus reconstruction (2 cases). The average examination time (including biopsy time) for all patients in our study was (22.5 依 15.5) min (ranged from 5 to 80 min). Of 73 examinations during which visible lesions were discovered, 241 biopsies were obtained in total with an average of 3.4 依 2.3 biopsies per examination (ranged from 1 to 9 biopsies per examination). Among them, there were 76 malignant biopsies (31.5% of 241, including 34 squamous cell carcinomas, 24 adenocarcinomas, 11 small cell lung cancers, 3 severe atypical hyperplasia, 2 adenoid cystic carcinomas, 1 adenosquamous carcinoma and 1 carcinoid) and 165 benign biopsies (68.5% of 241, including 124 slightmoderate chronic inflammations, 12 epithelial hypertrophy, 8 chronic inflammations with epithelial hypertrophy, 7 normal mucosa, 7 submucosal tuberculoses, 4 granulomas and 4 severe chronic inflammations). Among 76 malignant biopsies, 72 were identified by the AFB and 50 by the WLB. In terms of malignant lesions, the sensitivities, specificities, and NPVs of the AFB and WLB were 97.4% , 57% , 95.9% and 65.8% , 83.6% , 84.1% , respectively. These measured differences between the AFB and WLB were all statistically significant ( < 0.05) ( Table  1 ).
The AFB missed 1 squamous cell carcinoma, 1 adenocarcinoma, and 2 small cell lung cancers, each being a peripheral pulmonary lesion undetectable by bronchoscope. The WLB missed 10 squamous cell carcinomas, 10 adenocarcinomas, and 4 small cell lung cancers, including 15 central pulmonary lesions. All missed malignancies were identified by later biopsies. For either central or peripheral lesions, the accuracy of the AFB was significantly higher than the WLB (Tables 2 and 3 ).
Since highresolution CCD became an available imaging system, the definition and diagnostic power of bronchoscopes have improved remarkably. However, the most important tool for examining the bronchial mucosa, the commonly used WLB, is still plagued by limitations in diagnosing earlystaged mucosal lesions. More specifically, the WLB is ineffective at detecting lesions smaller than 5 mm in diameter and at differentiating nonspecific mucosal changes caused by hypertrophy or carcinoma in situ [5] . The AFB is a new technology that exploits the autofluorescent nature of the bronchial mucosa to detect tiny and superficial lesions. The AFB can identify abnormal mucosa in different colors without the assistance of drugs. Therefore, compared to the WLB, the AFB can better identify earlystaged mucosal lesions, thereby remarkably improving the bronchoscope爷s diagnostic efficiency for atypical hypertrophy and earlystaged cancer of the mucosa [1, 2] . As reported in the literature, the AFB detected tiny lesions that were only 1 mm in diameter or were several cellular layers in thickness. The AFB爷s sensitivity in detecting airway lesions was nearly 1.5 to 6.3fold stronger than the WLB (Table 4 ) [24, 69] . In the present study, the sensitivity of the AFB was significantly higher than the WLB (94.7% vs. 65.8% , 1.44:1), consistent with the literature. With central pulmonary lesions, the AFB爷s sensitivity was a remarkable 100% with no missed diagnoses, while the WLB爷 s missed diagnosis rate was 23.4%. This data suggests that the AFB has a higher diagnostic power on earlystaged cancer in the airway than the WLB.
Although the AFB could detect small changes in the bronchial mucosa with high sensitivity, it was unable to identify the pathology of any detected lesions. Indeed, the AFB distinguishes only the optical properties of tissues based on their thickness, blood supply, or extracellular matrix composition. In some lesions, such as inflammation, hyperemia, injury, and so on , mucos al thickness and blood supply increase, and the mucosa accordingly appears more red. It is difficult to distinguish those negative diseases from carcinoma. Therefore, the AFB爷s false negative rate for cancer is very high. The biggest limitations of the AFB were its low specificity and PPV. According to the literature, the AFB had either a lower specificity or PPV than the WLB. Similarly, in our study, the AFB had a lower specificity for malignancy than the WLB (57.0% vs. 83.6% ). This result may be due to the methodological limitations of the AFB, including its inability to make pathological diagnoses and its nonspecific response to other nonmalignant abnormalities in the bronchial mucosa. In addition, as a precaution for our inexperience at the onset of the study, we took biopsies for all areas that presented with abnormal colors to avoid missing diagnoses. Thus, our sampling approach might be another cause for the low specificity.
Low PPV and low specificity suggested more mucosal points for biopsy, leading to longer duration of mucosal injury, more fees, and longer examination time. Of the 136 cases analyzed, we found that the AFB had a significantly higher NPV (95.5% ) than the WLB, consistent with the literature (Table 5 ) [4, 7, 10] that usually reports an NPV > 95% for the AFB. A high NPV means that unnecessary biopsies can be avoided. Therefore, in our opinion, increased experience with the AFB will improve our examination techniques, resulting in reduced iatrogenic injury on the mucosa, increased ability to differentiate between hypertrophies and cancer, and fewer unnecessary biopsies. These improvements will reduce overall suffering from examinations and decrease examination fees and time.
In our study, the AFB was significantly more sensitive than the WLB in detecting adenocarcinoma and squamous cell carcinoma, but no similar effect was observed for small cell lung cancer. This differential detection may be due to the AFB爷s ability to identify lesions by optical changes in the bronchial mucosa but not by their pathology. Thus, as the AFB can only detect malignancies from the mucosa, it cannot easily detect small cell lung cancer, which usually arises from submucosal tissues. Further, as the present study included only 5 patients with 11 biopsies, more data are needed before any conclusions may be drawn.
According to the literature [1113] , applications for the AFB include (1) sputum examinations; (2) screening tests for populations at highrisk of developing lung cancer, including individuals with a cigarette smoking index 逸 400 and symptoms like prolonged cough or hemoptysis; (3) localization studies to identify the exact position and region of suspected lung cancer lesions; (4) reexaminations for airway recurrence after surgery to treat earlystaged lung cancer; and (5) studies to monitor therapeutic effects on tracheal tumors. Because the AFB is more sensitive than the WLB and can be used without any additional medicine, injury, examination time or fees, or special protective facilities, this new technology, in our opinion, should be suited to all cases receiving bronchoscopy. This is especially true for patients at highrisk for developing lung cancer, patients with centraltype lung cancer, or patients receiving postoperative recheck.
The AFB has a higher sensitivity than the WLB. By identifying the location of tumors, existence of multiple lesions, and recurrence of airway lesions, it improves the diagnostic efficiency of the bronchoscope for tracheobronchial mucosal cancer. The clinical value of AFB is, therefore, higher than the WLB.
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